Last reviewed · How we verify

calcipotriene + clobetasol propionate — Competitive Intelligence Brief

calcipotriene + clobetasol propionate (calcipotriene + clobetasol propionate) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical combination therapy (vitamin D analog + corticosteroid). Area: Dermatology.

marketed Topical combination therapy (vitamin D analog + corticosteroid) Vitamin D receptor (VDR) and glucocorticoid receptor (GR) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

calcipotriene + clobetasol propionate (calcipotriene + clobetasol propionate) — Leon Kircik, M.D.. Calcipotriene is a vitamin D analog that regulates skin cell differentiation and proliferation, while clobetasol propionate is a potent corticosteroid that suppresses inflammation and immune response in the skin.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
calcipotriene + clobetasol propionate TARGET calcipotriene + clobetasol propionate Leon Kircik, M.D. marketed Topical combination therapy (vitamin D analog + corticosteroid) Vitamin D receptor (VDR) and glucocorticoid receptor (GR)
Calcipotriene and betamethasone dipropionate ointment Calcipotriene and betamethasone dipropionate ointment Galderma R&D marketed Topical combination therapy (vitamin D analog + corticosteroid) Vitamin D receptor (VDR) and glucocorticoid receptor (GR)
Calcipotriene/betamethasone gel and ointment Calcipotriene/betamethasone gel and ointment LEO Pharma phase 3 Topical combination therapy (vitamin D analog + corticosteroid) Vitamin D receptor (VDR); glucocorticoid receptor (GR)
LEO 90105 = calcipotriol + betamethasone dipropionate LEO 90105 = calcipotriol + betamethasone dipropionate LEO Pharma phase 3 Topical combination therapy (vitamin D analog + corticosteroid) Vitamin D receptor (VDR); glucocorticoid receptor (GR)
Daivobet® gel Daivobet® gel LEO Pharma phase 3 Topical combination therapy (vitamin D analog + corticosteroid) Vitamin D receptor (VDR); glucocorticoid receptor (GR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical combination therapy (vitamin D analog + corticosteroid) class)

  1. LEO Pharma · 3 drugs in this class
  2. Galderma R&D · 1 drug in this class
  3. Leon Kircik, M.D. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). calcipotriene + clobetasol propionate — Competitive Intelligence Brief. https://druglandscape.com/ci/calcipotriene-clobetasol-propionate. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: